ArticleVaccine2016
Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis.
Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- PreclinicalFrontiers in immunology · 2025Article
- Progress toward a vaccine for extraintestinal pathogenicInfection and immunity · 2024Article
- A TonB dependent transporter YncD of Salmonella enterica Serovar Typhi possesses vaccine potential.World journal of microbiology & biotechnology · 2024Article
- NADeLife · 2024Article
- Genomic diversity, pathogenicity and antimicrobial resistance of Escherichia coli isolated from poultry in the southern United States.BMC microbiology · 2023Article
- Vaccination with a combination of planktonic and biofilm virulence factors confers protection against carbapenem-resistant Acinetobacter baumannii strains.Scientific reports · 2022Article
- Genomics and pathotypes of the many faces of Escherichia coli.FEMS microbiology reviews · 2022Article
- Extending applications of AFM to fluidic AFM in single living cell studies.Journal of cellular physiology · 2022Review
- Secreted Autotransporter Toxin (Sat) Mediates Innate Immune System Evasion.Frontiers in immunology · 2022Article
- The prevalence of the iutA and ibeA genes in Escherichia coli isolates from severe and non-severe patients with bacteremic acute biliary tract infection is significantly different.Gut pathogens · 2021Article
- Protection against avian pathogenic Escherichia coli and Salmonella Kentucky exhibited in chickens given both probiotics and live Salmonella vaccine.Poultry science · 2020Article
- Application of TonB-Dependent Transporters in Vaccine Development of Gram-Negative Bacteria.Frontiers in cellular and infection microbiology · 2020Review
- A new role for host annexin A2 in establishing bacterial adhesion to vascular endothelial cells: lines of evidence from atomic force microscopy and an in vivo study.Laboratory investigation; a journal of technical methods and pathology · 2019Article
- Immunization against poly-Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- UTI patients have pre-existing antigen-specific antibody titers against UTI vaccine antigens.Vaccine · 2019Article
- Oral Treatments With Probiotics and LiveFrontiers in microbiology · 2019Article
- Characterization of Spleen Transcriptome and Immunity Against Avian Colibacillosis After Immunization With Recombinant AttenuatedFrontiers in veterinary science · 2018Article
- Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach.Intensive care medicine · 2017Review
- Evaluation of Recombinant AttenuatedFrontiers in immunology · 2017Article
- A recombinant multi-antigen vaccine with broad protection potential against avian pathogenic Escherichia coli.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Systemic infections caused by extraintestinal pathogenic Escherichia coli (ExPEC) have emerged as the most common community-onset bacterial infections and are major causes of nosocomial infections worldwide. The management of ExPEC infections has been complicated by the heterogeneity of ExPEC strains and the emergence of antibiotic resistance, thus their prevention through vaccination would be beneficial. The protective efficacy of four common ExPEC antigen candidates composed of common pilus antigens EcpA and EcpD and iron uptake proteins IutA and IroN, were tested by both active and passive immunization in lethal and non-lethal murine models of sepsis. Additionally, antibody raised to a synthetic form of a conserved surface polysaccharide, β-(1-6)-linked poly-N-acetylglucosamine (dPNAG) containing 9 monomers of (non-acetylated) glucosamine (9GlcNH2) conjugated to tetanus toxoid TT (9GlcNH2-TT) was tested in passive immunization protocols. Active immunization of mice with recombinant antigens EcpA, EcpD, IutA, or IroN elicited high levels of total IgG antibody of IgG1/IgG2a isotypes, and were determined to be highly protective against E. coli infection in lethal and non-lethal sepsis challenges. Moreover, passive immunization against these four antigens resulted in significant reductions of bacteria in internal organs and blood of the mice, especially when the challenge strain was grown in iron-restricted media. Inclusion of antibodies to PNAG increased the efficacy of the passive immunization under conditions where the challenge bacteria were grown in LB medium but not in iron-restricted media. The information and data presented are the first step toward the development of a broadly protective vaccine against sepsis-causing E. coli strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.